Mu-opioid receptor–alpha-2A adrenergic receptor (MOR–α2A-AR) heterodimer complex (MOR–α2A-AR)

The Mu-opioid receptor–alpha-2A adrenergic receptor (MOR–α2A-AR) heterodimer complex is a functional molecular entity formed by the physical association of two distinct G protein-coupled receptors (GPCRs) (Vilardaga et al., 2008; Frontiers in Pharmacology, 2018). This complex is predominantly expressed in the central nervous system, particularly in the spinal cord and brain regions associated with nociception and reward (Jordan et al., 2003; PMC7363811). The heterodimerization results in unique pharmacological profiles and conformational cross-talk, where the activation of one receptor can directly influence the signaling state of the other (Vilardaga et al., 2008; Mol Pharmacol, 2003). For instance, morphine binding to MOR can induce a conformational switch that inhibits α2A-AR signaling, while the co-administration of agonists for both receptors often produces synergistic analgesic effects (Vilardaga et al., 2008; PMC4433353). This synergy is of high therapeutic interest as it may allow for effective pain management with reduced doses of opioids, thereby mitigating common side effects such as respiratory depression, tolerance, and addiction (PMC7363811; StatPearls, 2024). Consequently, the MOR–α2A-AR complex represents a promising target for the development of next-generation analgesics and strategies to combat the opioid crisis (Frontiers in Pharmacology, 2018).

Other names

MOR-alpha2A-AR complexMu-opioid receptor-alpha-2A adrenergic receptor heteromerOPRM1-ADRA2A heterodimerMOR-ADRA2A complexMu-opioid receptor–alpha-2A adrenoceptor complex

Synergistic antinociception through co-activation of MOR and alpha-2A adrenergic receptors; cross-conformational inhibition where MOR activation can suppress alpha-2A signaling; modulation of inhibitory G-protein (Gi/Go) pathways.